Willow Biosciences Inc. (CSE: WLLW) Developing Biosynthesis Platform for Production of Low-Cost, Pharmaceutical-Grade CBD
A joint development agreement signed with Noramco Inc., the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, is expected to scale the development of Willow’s CBD biosynthesis program The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, while the cannabinoid-based pharmaceuticals market may reach $50 billion by 2029 Synthetic biology is expected to disrupt the cannabinoid industry supply chain, providing access to new and larger markets for CBD and related compounds Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (APIs)…